Stem Cell Therapeutics Corp. Announces the Issuance of United States Patent Relating to Platelet Derived Growth Factor (PDGF)
May 18 2011 - 6:24PM
Marketwired
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS) ("SCT" or the
"Company") is pleased to announce today that it has been granted a
patent by the U.S. Patent and Trademark Office -U.S. Patent
7,943,376- entitled, "Platelet derived growth factor (PDGF)-derived
neurospheres define a novel class of progenitor cells." The claims
contained within this issued patent cover methods of using PDGF to
produce neural progenitor populations which can differentiate into
neurons and oligodendrocytes but not astrocytes. The use of
PDGF-enriched progenitor cells can be used to treat or ameliorate
neural diseases or conditions associated with neuron or
oligodendrocytes loss or dysfunction, such as Stroke, Multiple
Sclerosis, Traumatic brain injury, Parkinson's Disease and
Alzheimer's Disease.
Dr. Allen Davidoff, SCT's Chief Scientific Officer, commented as
follows:
"PDGF derived neurons are a cell type that appear to be well
suited for the treatment of Parkinson's Disease and potentially for
other chronic neurologic disease's. This issued patent continues to
add value to our intellectual property (IP) and demonstrates SCT
ongoing commitment to the protection and development of its novel
IP in the field of central nervous system disease. "
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp.
is a public biotechnology company (TSX VENTURE: SSS) focused on the
development and commercialization of drug-based therapies to treat
central nervous system diseases. SCT is a leader in the development
of therapies that utilize drugs to stimulate a patient's own
resident stem cells. The Company's programs aim to repair brain and
nerve function lost due to disease or injury. The Company's
extensive patent portfolio of owned and licensed intellectual
property supports the potential expansion into future clinical
programs in numerous neurological diseases such as Stroke,
traumatic brain injury, multiple sclerosis, Huntington's disease,
Alzheimer's disease, and ALS.
These securities have not been registered under the United
States Securities Act of 1933, as amended, or the securities laws
of any state, and may not be offered or sold within the United
States or to, or for the account or benefit of U.S. persons unless
an applicable exemption from U.S. registration requirements is
available.
Except for historical information, this press release may
contain forward-looking statements, which reflect the Company's
current expectation regarding future events. These forward-looking
statements involve risk and uncertainties, which may cause but are
not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of
corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to
time in the Company's ongoing quarterly and annual reporting.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contacts: Stem Cell Therapeutics Corp. Allen Davidoff, PhD CSO
403-245-5495 ext.226 adavidoff@stemcellthera.com Stem Cell
Therapeutics Corp. Michael Cook CFO 403-245-5495 ext.229
mcook@stemcellthera.com www.stemcellthera.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024